VIP-SPOT: an Innovative Assay To Quantify the Productive HIV-1 Reservoir in the Monitoring of Cure Strategies.
Anti-Retroviral Agents
/ therapeutic use
CD4-Positive T-Lymphocytes
/ virology
DNA, Viral
/ genetics
Disease Reservoirs
/ virology
Enzyme-Linked Immunospot Assay
/ methods
HIV Infections
/ drug therapy
HIV-1
/ chemistry
Humans
Proviruses
/ genetics
Retrospective Studies
Single-Cell Analysis
/ methods
Viral Load
/ methods
Viral Proteins
/ analysis
Viremia
/ virology
Virus Latency
HIV-1
HIV-1 cure
HIV-1 latent reservoir
HIV-1 reservoir size
Journal
mBio
ISSN: 2150-7511
Titre abrégé: mBio
Pays: United States
ID NLM: 101519231
Informations de publication
Date de publication:
29 06 2021
29 06 2021
Historique:
pubmed:
23
6
2021
medline:
16
11
2021
entrez:
22
6
2021
Statut:
ppublish
Résumé
Improved assays are critical to the successful implementation of novel HIV-1 cure strategies, given the limited ability of currently available assays to quantify true effects on the viral reservoir. As interventions based on immune clearance target infected cells producing viral antigens, irrespective of whether the viruses generated are infectious or not, we developed a novel assay to identify viral protein production at the single-cell level. The novel viral protein spot (VIP-SPOT) assay, based on the enzyme-linked ImmunoSpot (ELISpot) approach, quantifies the frequency of CD4
Identifiants
pubmed: 34154408
doi: 10.1128/mBio.00560-21
pmc: PMC8262951
doi:
Substances chimiques
Anti-Retroviral Agents
0
DNA, Viral
0
Viral Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0056021Commentaires et corrections
Type : ErratumIn
Références
Nat Med. 2020 Sep;26(9):1339-1350
pubmed: 32895573
J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Apr 15;20(5):442-7
pubmed: 10225225
PLoS One. 2017 Apr 17;12(4):e0175899
pubmed: 28414780
PLoS Pathog. 2019 Feb 27;15(2):e1007619
pubmed: 30811499
J Clin Invest. 2018 Feb 1;128(2):876-889
pubmed: 29355843
Nature. 2019 Feb;566(7742):120-125
pubmed: 30700913
J Clin Virol. 2007 May;39(1):1-8
pubmed: 17387039
J Virol. 2020 Apr 16;94(9):
pubmed: 32051267
Nat Commun. 2021 Jan 8;12(1):165
pubmed: 33420062
Front Immunol. 2020 Aug 06;11:1971
pubmed: 32849659
JCI Insight. 2017 Aug 17;2(16):
pubmed: 28814661
Curr HIV/AIDS Rep. 2017 Apr;14(2):72-81
pubmed: 28401492
Nat Med. 2016 Sep;22(9):1043-9
pubmed: 27500724
J Exp Med. 2019 Oct 7;216(10):2253-2264
pubmed: 31350309
Retrovirology. 2018 Jan 29;15(1):13
pubmed: 29378657
Sci Transl Med. 2018 Feb 28;10(430):
pubmed: 29491188
Nature. 2019 Dec;576(7787):397-405
pubmed: 31853080
Proc Natl Acad Sci U S A. 2014 May 13;111(19):7078-83
pubmed: 24706775
EMBO J. 2003 Apr 15;22(8):1868-77
pubmed: 12682019
J Virol. 2017 Feb 28;91(6):
pubmed: 28077644
Adv Exp Med Biol. 2018;1075:285-318
pubmed: 30030798
J Clin Virol. 2004 Jan;29(1):33-8
pubmed: 14675867
J Virol. 1986 Aug;59(2):284-91
pubmed: 3016298
mBio. 2018 Nov 13;9(6):
pubmed: 30425153
EBioMedicine. 2015 Jun 27;2(8):874-83
pubmed: 26425694
Nature. 1997 May 8;387(6629):183-8
pubmed: 9144289
J Virol. 2021 Feb 24;95(6):
pubmed: 33361426
AIDS. 2014 Sep 10;28(14):2157-9
pubmed: 25265080
J Antimicrob Chemother. 2018 Jul 1;73(7):1940-1948
pubmed: 29635527
Cell Host Microbe. 2016 Sep 14;20(3):368-380
pubmed: 27545045
J Infect Dis. 2021 Oct 13;224(7):1209-1218
pubmed: 32147687
Cell. 2013 Oct 24;155(3):540-51
pubmed: 24243014
Proc Natl Acad Sci U S A. 2020 Feb 18;117(7):3704-3710
pubmed: 32029589
Sci Transl Med. 2020 Jan 29;12(528):
pubmed: 31996465
J Infect Dis. 2017 Mar 15;215(suppl_3):S134-S141
pubmed: 28520968
Clin Infect Dis. 2021 Feb 1;72(3):495-498
pubmed: 33527127